title: The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma.
abstract: BACKGROUND
  The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.
  
  
  METHODS
  Herein we present two cases where fulvestrant, as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who present with varying degrees of intestinal obstruction.
  
  
  CONCLUSIONS
  Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity, in appropriately selected patients.
authors.affiliation: Division of Breast Surgery, University of Nottingham, Nottingham, UK. jaytea@gmail.com
authors.forename: Jasmine Y M
authors.initials: JY
authors.lastname: Tang
authors.forename: Rajendra Singh
authors.initials: RS
authors.lastname: Rampaul
authors.forename: Kwok L
authors.initials: KL
authors.lastname: Cheung
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology*; D008875:Middle Aged; D009362:Neoplasm Metastasis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000077267:Fulvestrant; D004958:Estradiol